Top

Gepubliceerd in:

01-01-2013 | Point of View

Beta-blocker therapy in unstable severe heart failure, evidence or experience?

Auteurs: C. L. Meuwese, J. H. Kirkels, N. de Jonge, H. M. Nathoe, P. A. Doevendans, C. Klöpping

Gepubliceerd in: Netherlands Heart Journal | Uitgave 1/2013

Abstract

Currently, no evidence exists on the effects of beta-receptor blocker (BRB) treatment in patients with unstable severe heart failure. When confronted with this specific patient category, clinical experience in our centre has consistently guided us to lower the dose or stop BRB therapy. To share this experience, we present three clinical case scenarios and discuss background literature motivating our approach in these patients.

vorige artikel Choosing wisely or beyond the guidelines

volgende artikel Myocardial bridging: what have we learned in the past and will new diagnostic modalities provide new insights?

Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022–36.PubMedCrossRef

Swedberg K, Hjalmarson A, Waagstein F, et al. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979;1:1374–6.PubMedCrossRef

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13.

Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group. N Engl J Med. 1996;334:1349–55.PubMedCrossRef

Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA. 2000;283:1295–302.PubMedCrossRef

Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962;267:650–4.PubMedCrossRef

Haeck ML, Hoogslag GE, Rodrigo SF, et al. Treatment options in end-stage heart failure: where to go from here? Neth Heart J. 2012;20:167–75.

Boerlage-van Dijk K, Meregalli PG, Planken RN, Koch KT, Baan J Jr. Percutaneous left ventricular partitioning device for chronic heart failure. Neth Heart J. 2012 Nov 1. doi:10.1007/s12471-012-0331-5

Luttik ML, Brons M, Jaarsma T, et al. Design and methodology of the COACH-2 (Comparative study on guideline adherence and patient compliance in heart failure patients) study: HF clinics versus primary care in stable patients on optimal therapy. Neth Heart J. 2012;20:307–12.

10.

Kortekaas KA, Lindeman JH, Versteegh MI, Stijnen T, Dion RA, Klautz RJ. Preexisting heart failure is an underestimated risk factor in cardiac surgery. Neth Heart J. 2012;20:202–7.

11.

van der Wall EE. Cardiac resynchronisation improves survival in mild heart failure! Neth Heart J. 2011;19:103–4.

12.

Klöpping C, Kirkels JH, de Jonge N. Beta-blocking agents in congestive heart failure: for each heart failure patient? Neth Heart J. 2005;13:163–4.

13.

Jondeau G, Neuder Y, Eicher JC, et al. B-CONVINCED: beta-blocker continuation vs. interruption in patients with congestive heart failure hospitalized for a decompensation episode. Eur Heart J. 2009;30:2186–92.PubMedCrossRef

14.

Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–54.PubMedCrossRef

15.

Beck-da-Silva L, de Bold A, Davies R, et al. Effect of bisoprolol on right ventricular function and brain natriuretic peptide in patients with heart failure. Congest Heart Fail. 2004;10:127–32.PubMedCrossRef

16.

Tatli E, Kurum T, Aktoz M, et al. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure. Int J Cardiol. 2008;125:273–6.PubMedCrossRef

17.

Desai RV, Guichard JL, Mujib M et al. Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: Insights from the BEST trial. Int J Cardiol 2011;Ahead of print.

18.

Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002;40:1248–58.PubMedCrossRef

19.

Bollano E, Tang MS, Hjalmarson A, et al. Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart. 2003;89:621–4.PubMedCrossRef

20.

Jennings DL, Thompson ML. Use of combination therapy with a beta-blocker and milrinone in patients with advanced heart failure. Ann Pharmacother. 2009;43:1872–6.PubMedCrossRef

Titel: Beta-blocker therapy in unstable severe heart failure, evidence or experience?
Auteurs: C. L. Meuwese
J. H. Kirkels
N. de Jonge
H. M. Nathoe
P. A. Doevendans
C. Klöpping
Publicatiedatum: 01-01-2013
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Netherlands Heart Journal / Uitgave 1/2013
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI: https://doi.org/10.1007/s12471-012-0366-7

Andere artikelen Uitgave 1/2013

Quality of life research, it’s only the beginning

Editorial Comment

Palpitations, once again

Rhythm Puzzle - Answer

A cataclasm due to spasm

Case Report

Myocardial bridging: what have we learned in the past and will new diagnostic modalities provide new insights?

Review Article

Choosing wisely or beyond the guidelines

Editor's comment

The effect of aortic valve replacement on quality of life in symptomatic patients with severe aortic stenosis

Original Article – E-LEARNING